Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202301193813i

Article Source : Business Wire
Link : https://www.businesswire.com/news/home/20221123005365/en/Qurient-Announces-Dosing-of-First-Patient-in-Q901-Phase-12-Clinical-Study-for-the-Treatment-of-Patients-with-Solid-Tumors

Article Source : 머니투데이
Link : https://news.mt.co.kr/mtview.php?no=2022120109525454587

Article Source : 약업신문
Link : https://www.yakup.com/news/index.html?mode=view&cat=12&nid=274957

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202210316313i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202209278442i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202210055579i

Article Source : Business Wire
Link : https://www.businesswire.com/news/home/20220914005974/en/Qurient-Announces-Collaboration-Agreement-with-MSD-to-Evaluate-Selective-CDK7-Inhibitor-Q901-in-Combination-With-KEYTRUDA%C2%AE-pembrolizumab

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202209148645i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202209064664i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202202167893i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202202142087i

Article Source : Businesswire
Link : https://www.businesswire.com/news/home/20220208005826/en/Qurient-Announces-U.S.-FDA-Clearance-of-IND-Application-for-Q901-a-Novel-Cancer-Therapy

Article Source : 메디컬투데이
Link : https://mdtoday.co.kr/news/view/1065590131030960